about
TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression.Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.Higher HOPX expression is associated with distinct clinical and biological features and predicts poor prognosis in de novo acute myeloid leukemiaExpression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse modelA knock-in Npm1 mutation in mice results in myeloproliferation and implies a perturbation in hematopoietic microenvironmentThe N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expressionClinical and prognostic implications of Roundabout 4 (robo4) in adult patients with acute myeloid leukemia.Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adultsHigh Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan.Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study.SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.An mRNA expression signature for prognostication in de novo acute myeloid leukemia patients with normal karyotype.Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemiaReduced incidence of interstitial pneumonitis after allogeneic hematopoietic stem cell transplantation using a modified technique of total body irradiation.Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).Dynamic contrast-enhanced MR imaging measurement of vertebral bone marrow perfusion may be indicator of outcome of acute myeloid leukemia patients in remission.Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.Aurora A and NF-κB Survival Pathway Drive Chemoresistance in Acute Myeloid Leukemia via the TRAF-Interacting Protein TIFA.Prognostic significance of NPM1 mutation-modulated microRNA-mRNA regulation in acute myeloid leukemia.MicroRNA let-7a-3 gene methylation is associated with karyotyping, CEBPA promoter methylation, and survival in acute myeloid leukemia.Gfi-1 is the transcriptional repressor of SOCS1 in acute myeloid leukemia cells.The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies.Overexpression of SOX4 correlates with poor prognosis of acute myeloid leukemia and is leukemogenic in zebrafishReply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'.Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia.Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia.IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia.Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection.A 3-microRNA scoring system for prognostication in de novo acute myeloid leukemia patients.SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.Chromosomal abnormalities by conventional cytogenetics and interphase fluorescence in situ hybridization in chronic lymphocytic leukemia in Taiwan, an area with low incidence--clinical implication and comparison between the West and the East.Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.
P50
Q27851661-8F079DEA-1650-45A4-A415-87B2E677591FQ27852437-3ECC1C2C-F5FB-464E-88DA-D25F650426B7Q33416982-D4ED50D7-8D03-4319-8679-F393E5875A66Q33746724-EE6C2E8D-24E8-47E6-83E7-C68A36A551F7Q33846806-F833B1FA-0215-4457-8182-DB1D1D820CDAQ33892323-3D803C7D-1918-43D1-8A2B-61B06577B25DQ34505038-DAAE03FE-48F0-4C92-9119-1A636D82CE5AQ34649120-D13C8E2C-B73A-4FC1-93E4-2283CA2AFC7EQ35203340-ABEE0EF6-71EE-4776-ABF6-F0147BA62649Q35568696-6A323D74-726D-44E4-B4E0-A30C5B2316E6Q35659664-7A6B4AF1-02FD-43AF-80DA-C05164114756Q35778467-0BCF6BDB-549A-4A05-81E5-01B9E9BA1315Q35849733-1477E6C5-B80F-4D30-9105-F8AF4267936BQ35921904-7BAD59CF-A2D0-4649-B688-14DDDC41D2DBQ36629521-79435035-6BAB-41D7-BD5F-C78B13C11360Q36962514-728D7F19-808B-4DBE-BFF1-9DEB5A12AAF3Q37405638-6916349C-E348-410F-B1E5-0242C3A65D2FQ37641801-2563236A-8432-4FEA-89F7-EF0E92C09C65Q37665288-55488947-ABA2-4E67-9961-588A8614C23AQ37826588-4DC4CB7C-3CEB-4429-8E1F-467634DC745CQ38703904-59E8046D-78C2-44ED-A950-C409B29670DCQ38722212-4A818F2A-1093-43CC-A835-D8939AFA8E47Q38834968-D159F0EA-A92C-4F60-838C-EF5103339A77Q39007744-34FC1735-67C4-4353-9B4F-78E0654E833FQ39098228-3EA8AB83-3CB3-45D5-8072-B34C19EC24D5Q40337532-63C1EFC4-3C27-4EFE-AC86-EC34EF42AA66Q41177054-BC7B361F-1AD7-4A82-8D5F-E72B55171134Q42543838-470C05BC-214E-4DE4-8CE8-0FC9E06E186FQ43185220-FA4F594B-35EA-435B-9A41-DEB778398D00Q43466307-390410D6-B763-4815-B999-89FE1D0FEF11Q44556847-EF60AF56-E239-4D55-B04B-86065A2C0934Q45719667-7BF4974E-806B-4E0C-982E-4A32670AA737Q46111829-E425F703-8D43-4EEA-AE17-67EDF7A3C086Q46606851-A2DF3CA3-189B-4EAB-BDAC-62815F556C4BQ49048040-1C445F01-41D8-4B71-874D-E178CE39210CQ50609353-84C20F95-25A4-4452-A8C8-8CE50925749CQ53058458-910FD275-064B-47B2-9E92-01CEA0941F47Q53086529-23AD8080-69B7-4473-A1E5-1543BD4650FCQ53119796-2CAF394E-6FAE-40F7-99BB-01D8E2FCD19BQ55025720-7B476BF1-8669-40E1-9F5F-30FB00909C65
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Hsin-An Hou
@ast
Hsin-An Hou
@en
Hsin-An Hou
@es
Hsin-An Hou
@nl
type
label
Hsin-An Hou
@ast
Hsin-An Hou
@en
Hsin-An Hou
@es
Hsin-An Hou
@nl
prefLabel
Hsin-An Hou
@ast
Hsin-An Hou
@en
Hsin-An Hou
@es
Hsin-An Hou
@nl
P106
P1153
22834730900
P31
P496
0000-0003-2780-4845